Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 13/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.44 |
| ▸ | HTR1A | P08908 | 7/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5995472 | 0.88 | SLC6A2 (0.34) | SLC6A2SLC6A3SLC6A4HTR1ALMNA | |
| SCHEMBL5996258 | 0.86 | SLC6A2 (0.45) | SLC6A2SLC6A3SLC6A4CYP2D6HRH1 | |
| SCHEMBL7280300 | 0.81 | ADRA2A (0.35) | SLC6A2SLC6A3SLC6A4LMNACYP2D6 | |
| SCHEMBL5993827 | 0.81 | TDP1 (0.32) | SLC6A2SLC6A3SLC6A4CYP1A2CYP2D6 | |
| SCHEMBL934920 | 0.72 | SLC6A2 (0.64) | SLC6A2SLC6A3SLC6A4HTR1ACYP2D6 | |
| SCHEMBL934190 | 0.72 | SLC6A2 (0.64) | SLC6A2SLC6A3SLC6A4HTR1ACYP2D6 | |
| SCHEMBL934191 | 0.72 | SLC6A2 (0.64) | SLC6A2SLC6A3SLC6A4HTR1ACYP2D6 | |
| SCHEMBL27870128 | 0.71 | SLC6A2 (0.45) | SLC6A2SLC6A3SLC6A4HTR1AALDH1A1 | |
| SCHEMBL6701385 | 0.68 | SLC6A3 (0.42) | SLC6A2SLC6A3SLC6A4ALDH1A1LMNA | |
| SCHEMBL6455895 | 0.67 | SLC6A2 (0.41) | SLC6A2SLC6A3SLC6A4HTR1ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7026321-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2006-04-11 | — | — | US | disclosed |
| US-20040186109-A1 | piperazine derivatives, e.g., (2R)-1-(2-methylbenzothiazol-5-yloxy)-3-[4-({5-[4-(trifluoromethyl)phenyl](4,5-dihydroisoxazol-3-yl)}methyl)piperazinyl]propan-2-ol; treating diabetes, arrhythmia, intermittent claudication, angina, congestive heart disease, and myocardial infarction | CV THERAPEUTICS, INC. | 2004-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186109-A1 | piperazine derivatives, e.g., (2R)-1-(2-methylbenzothiazol-5-yloxy)-3-[4-({5-[4-(trifluoromethyl)phenyl](4,5-dihydroisoxazol-3-yl)}methyl)piperazinyl]propan-2-ol; treating diabetes, arrhythmia, intermittent claudication, angina, congestive heart disease, and myocardial infarction | KCNJ2, PPARA, PPARD | SLC6A2 4763/4885SLC6A3 4596/4885SLC6A4 4357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.